Topics in Anti-Cancer Research

Volume 1


Atta-ur-Rahman / Khurshid Zaman

DOI: 10.2174/97816080547871120101
eISBN: 978-1-60805-478-7, 2012
ISBN: 978-1-60805-612-5
ISSN: 2468-5860 (Print)
ISSN: 2213-3585 (Online)

Recommend this Book to your Library or Friend

Indexed in: Book Citation Index, Science Edition, Chemical Abstracts, BIOSIS Previews, EBSCO, Ulrich's Periodicals Directory.

The Topics in Anti-Cancer Research eBook series covers important advances on both experimental (preclinical) and clinical cancer resea...[view complete introduction]
US $
Buy Personal Book
Order Library Book
Order Printed Copy
Order PDF + Printed Copy (Special Offer)

*(Excluding Mailing and Handling)

ūüĒíSecure Checkout Personal information is secured with SSL technology
Download Flyer

Table of Contents


- Pp. i-iii (3)
Atta-ur-Rahman and Dr. Khurshid Zaman
Download Free

List of Contributors

- Pp. iv-v (2)
Atta-ur-Rahman and Dr. Khurshid Zaman
Download Free


- Pp. vi- (1)
Atta-ur-Rahman and Dr. Khurshid Zaman
Download Free

Silencing Human Cancer: Identification and Uses of MicroRNAs

- Pp. 3-30 (28)
Francisco E. Nicolas, Sara Lopez-Gomollon, Alfonso F. Lopez-Martinez and Tamas Dalmay

PDF Price: $15

View Abstract Purchase Chapter

Insulin-Like Growth Factor Receptor Inhibitors: Categorical Lack of Efficacy or Lack of Personalised Medicine?

- Pp. 31-89 (59)
Madeleine Hewish, Ian Chau and David Cunningham

PDF Price: $15

View Abstract Purchase Chapter

Heparan Sulfate Proteoglycans: Novel Targets for Breast Cancer Treatment

- Pp. 90-112 (23)
Chuay-Yeng Koo, Yin-Ping Sen, Boon-Huat Bay and George W. Yip

PDF Price: $15

View Abstract Purchase Chapter

Adjuvant Therapy for Renal Cell Carcinoma

- Pp. 113-139 (27)
Sebastiano Buti, Melissa Bersanelli, Maddalena Donini and Andrea Ardizzoni

PDF Price: $15

View Abstract Purchase Chapter

Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma

- Pp. 140-175 (36)
Emmanuel Seront and Jean-Pascal Machiels

PDF Price: $15

View Abstract Purchase Chapter

Rationale for an Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer

- Pp. 176-191 (16)
Paul H. Sugarbaker, Dal Yoo, O. Anthony Stuart and Lana Bijelic

PDF Price: $15

View Abstract Purchase Chapter

Restoring p53 Function: Novel Anticancer Approaches for an Old Foe

- Pp. 192-227 (36)
Alessandra Leone, Alessandra Di Cintio, Elena Di Gennaro, Francesca Bruzzese and Alfredo Budillon
View Abstract Download Free

Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Application

- Pp. 228-253 (26)
Ahmad F. Hussain, Ulrich Wullner, Inga Neef, Mehmet K. Tur and Stefan Barth

PDF Price: $15

View Abstract Purchase Chapter

Personalized Medicine for Pediatric AML: New Targeted Strategies

- Pp. 254-290 (37)
Riccardo Masetti, Katharina Kleinschmidt, Carlotta Biagi and Andrea Pession

PDF Price: $15

View Abstract Purchase Chapter

Pharmacology and Clinical Efficacy of Cladribine in Hematological Malignancies - Older and Newer Formulations

- Pp. 291-333 (43)
Tadeusz Robak, Anna Korycka-Wolowiec and Ewa Robak

PDF Price: $15

View Abstract Purchase Chapter

Current Treatment Options in the Management of Locally Advanced Squamous Cell Cancers of Head and Neck

- Pp. 334-367 (34)
Shahzad Raza, Areej Khan, Monis Khan, Jaffar A. Al-Hilli, Mahadi A. Baig, Tulay Aksoy, Madhumati R. Kalavar and Rashmi Ramasubbaiah

PDF Price: $15

View Abstract Purchase Chapter

Compounds with Anti-Inflammatory Effect Used for Preventing or Regressing Tumors

- Pp. 368-391 (24)
Ricardo de Souza Pereira and Josiele Latties

PDF Price: $15

View Abstract Purchase Chapter

Author Index

- Pp. 392- (1)
Atta-ur-Rahman and Khurshid Zaman
Download Free

Subject Index

- Pp. 393-414 (22)
Atta-ur-Rahman and Khurshid Zaman
Download Free


Topics in Anti-Cancer Research covers important advances on both experimental (preclinical) and clinical cancer research in drug development. Major developments in the fields of oncology are covered including mechanisms, tumor and stem cell biology, metastasis, tumor suppressors, cancer drug targets, drug clinical trials, cellular and molecular pathology, genomics and genetics, diagnostics, translational therapeutics, tumor immunology, and cancer prevention and epidemiology. Topics in Anti-Cancer Research is an essential e-book for oncologists, pharmaceutical scientists, clinicians and researchers in other related disciplines.

The first volume of Topics in Anti-Cancer Research comprises comprehensive chapters contributed by eminent experts in their respective field, who have also earlier contributed to and published in Recent Patents on Anti-Cancer Drug Discovery.

Nicolas et al. present the mechanism of action of miRNAs, identification of oncogenes and tumor suppressor genes in cancer diagnosis and treatment in Chapter 1. Recent studies on a new class of negative regulators involved in the repression of gene expression have also been reviewed.

Chapter 2 by Hewish et al. focuses on preclinical studies, clinical trials and recent data on insulin-like growth factor 1 receptor inhibitors i.e. figitumumab (CP-751,871), cixutumumab (IMC-A12), ganitumab (AMG-479), dalotuzumab (MK-0646), robatumumab (R1507), the IGF-1R tyrosine kinase inhibitors linsitinib (OSI-906), XL228 and AXL1717 as potential target for cancer treatment, and newly developed agents, including the IGF-1/IGF-2 neutralizing antibody MEDI-573 for determining the resistance and efficacy.

Heparan sulfate proteoglycans are present at the surfaces of all cells and are involved in the modulation of various molecular signaling pathways related to tumor progression. Yip et al. discuss the recent patented use, clinical trials and regulation of novel inhibitors heparan sulfate proteoglycans as therapeutic targets for the treatment of breast cancer, which is one of the primary causes of female deaths all over the world.

New adjuvant therapies for the treatment of renal cell carcinoma after surgery are described by Buti et al. in Chapter 4. Recent Phase III adjuvant trials are also briefly reviewed. A comprehensive review of the recent targeted therapies in clinical practice to treat patients with metastatic unresectable renal cell carcinoma and drug-associated complications (bevacizumab, sorafenib, sunitinib, pazopanib, axitinib, everolimus , emsirolimus, and axitinib) is presented in Chapter 5 by Seront et al.

Sugarbaker et al. describe the recently available theoretical medical information on the use of intrperitoneal gemcitabine applicable to patients with resected pancreatic adenocarcinoma.

Budillon et al. focus on recent approaches of p53 as anticancer therapeutical target and their understanding to restore p53 function in cancer.

In Chapter 8, Barth et al. have presented an overview of the current developments in the field of siRNA/shRNA delivery and present progress of efficient small RNA delivery methods, pharmacokinetic properties to promote their cellular uptake, their advantages and disadvantages and the corresponding clinical trials.

Masetti et al. present a review on the treatment of acute myeloid leukemia in children with recently patented novel molecularly targeted new drugs i.e. monoclonal antibodies, inhibitors of signalling molecules, proteasome inhibitors and epigenetic agents. Analysis of the previous published preclinical data and the clinical trials are also discussed in Chapter 9.

Chapter 10 by Robak et al. summarizes the current understanding of the mechanism of action of cladribine 2-CdA in hematological malignancies, studies on recent pharmacokinetics of different patented pharmaceutical formulations, ongoing trials and potential future applications in the treatment of hematological malignancies.

Raza et al. address new development and recent clinical trials on Cetuximab, tyrosine kinase inhibitors (gefitinib and erlotinib), Vandetanib and EGFR for treatment in patients with locally advanced head and neck squamous cell cancers (HNSCCs) in Chapter 11. Recent patents on hypoxia-inducible factor 1 alpha, mesenchymal-epithelial transition factor, insulin-like growth factor or the PI3K/AKT/mTOR pathway, and farnesyl transferase inhibitors that have been used in the management of HNSCCs are discussed.

Ricardo De Souza Pereira discusses comprehensive recent patents and scientific literature on anti-cancer effect of anti-inflammatory drugs in Chapter 12. Resveratrol and SB-73 and the derivatives are selective COX-2 inhibitors possessing anti-inflammatory and anti-cancer properties. The application of NSAID in cancer treatment has also been reviewed.

It is hoped that the present volume will be of interest to a large number of medicinal chemists, pharmacologists, clinicians and medical doctors interested in learning about current frontiers in cancer chemotherapy.

The editors wish to express their sincere gratitude to Mr. Mahmood Alam, Ms. Raheela Anjum, Ms. Iffat Shaheen and Mrs. Rafia Rehan, the reviewers and all colleagues for their assistance in the finalization of eBook.

Atta-ur-Rahman, FRS
Kings College,
University of Cambridge,

Dr. Khurshid Zaman
Bentham Science Publishers

List of Contributors

Atta-ur-Rahman / Khurshid Zaman
University of Cambridge

Barth, Stefan
Frauhofer IME
Forckenbeckstr. 6
Aachen, 52074

Budillon, Alfredo
Department of Research
Istituto Nazionale Tumori
Via M. Semmola
Napoli, 80131

Buti, Sebastiano
Operative Unit of Medical Oncology
University Hospital of Parma
Via Gramsci 14
Parma, 43100

Hewish, Madeleine
Department of Medicine
Royal Marsden Hospital
Downs Road
United Kingdom

Machiels, Jean-Pascal
Medical Oncology Unit
Université catholique de Louvain
Cliniques universitaires Saint-Luc
10 Avenue Hippocrate
Brussels, 1200

Masetti, Riccardo
Paediatric Oncology and Haematology Unit ‚ÄúLalla Ser√†gnoli‚ÄĚ
Sant’Orsola-Malpighi Hospital
Via Massarenti 11
Bologna, 40138

Nicolas, Francisco E.
Department of Genetics and Microbiology
University of Murcia
Regional Campus of International Excellence "Campus Mare Nostrum"
Murcia, 30100

Pereira, Ricardo de Souza
Universidade Federal do Amap√°
Colegiado de Farm√°cia
Campus Universit√°rio Marco Zero do Equador Rod
Juscelino Kubitschek, KM-02, Jardim Marco Zero

Raza, Shahzad
Division of Hematology & Oncology
Ellis Fischel Cancer Center
University of Missouri Health Care Columbia
MO, 65203

Robak, Tadeusz
Department of Hematology
Medical University of Lodz
93-513 ŇĀ√≥dŇļ, Pabianicka 62

Sugarbaker, Paul H.
Washington Cancer Institute
106 Irving St. NW
Suite 3900
DC, 20010

Yip, George W.
Department of Anatomy
Yong Loo Lin School of Medicine
National University of Singapore
4 Medical Drive, Block MD 10, Singapore


Webmaster Contact: Copyright © 2019 Bentham Science